Evidence map›Paper›PMID 27195814›Full record

Trial reportJAMA2016

Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.

Jeff D Williamson, Mark A Supiano, William B Applegate, Dan R Berlowitz, Ruth C Campbell, Glenn M Chertow, Larry J Fine, William E Haley, Amret T Hawfield, Joachim H Ix and 16 more

Registry-linked trialOpen access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in JAMA, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01206062 (Systolic Blood Pressure Intervention Trial), which is not on this map. Cited by 549 papers, 18 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
549citing papers in PubMed, 18 pooled it
123.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01206062 nacompletednot on this map

Systolic Blood Pressure Intervention Trial

TypeinterventionalSponsorNational Heart, Lung, and Blood Institute (NHLBI)Ran2010 to 2019Enrolled9,361ConditionsHypertensionArmsIntensive control of SBP, Standard control of SBP
3 · Its place in the literature

Who cites it

549 citing papers in PubMed, 18 syntheses or guidelines pooled it, 1,223 citations in OpenAlex.

  1. Pooled it
  2. The Japanese Society of Hypertension Guidelines for the management of elevated blood pressure and hypertension 2025 (JSH2025).Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Guideline
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Guideline
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Pooled it
  19. Trial
  20. Trial

489 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors at 17 institutions in 1 country.

Jeff D WilliamsonSection on Gerontology and Geriatric Medicine, Wake Forest School of Medicine, Department of Internal Medicine, Winston-Salem, North Carolina.
Mark A SupianoDivision of Geriatrics, School of Medicine, University of Utah, Salt Lake City3Veterans Affairs Salt Lake City, Geriatric Research, Education, and Clinical Center, Salt Lake City, Utah.
William B ApplegateSection on Gerontology and Geriatric Medicine, Wake Forest School of Medicine, Department of Internal Medicine, Winston-Salem, North Carolina.
Dan R BerlowitzBedford Veterans Affairs Hospital, Bedford, Massachusetts5School of Public Health, Boston University, Boston, Massachusetts.
Ruth C CampbellDepartment of Medicine, Medical University of South Carolina, Charleston.
Glenn M ChertowDepartment of Medicine, Stanford University School of Medicine, Palo Alto, California.
Larry J FineClinical Applications and Prevention Branch, Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, Maryland.
William E HaleyDepartment of Nephrology and Hypertension, Mayo Clinic, Jacksonville, Florida.
Amret T HawfieldSection on Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina.
Joachim H IxDivision of Nephrology and Hypertension, Department of Medicine, University of California, San Diego12Division of Preventive Medicine, Department of Family Medicine and Public Health, University of California, San Diego13Department of Medicine, Nephrology.
Dalane W KitzmanSection on Cardiovascular Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina.
John B KostisCardiovascular Institute at Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey.
Marie A Krousel-WoodDepartment of Medicine, Tulane University School of Medicine, New Orleans, Louisiana17Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana18Center for Applied Health Research, Ochsner Clinic F.
Lenore J LaunerIntramural Research Program, National Institute on Aging, Bethesda, Maryland.
Suzanne OparilDivision of Cardiovascular Disease, Department of Medicine, University of Alabama, Birmingham.
Carlos J RodriguezDivision of Public Health Sciences, Department of Epidemiology and Prevention, Wake Forest School of Medicine, Winston-Salem, North Carolina.
Christianne L RoumieVeterans Health Administration-Tennessee Valley Healthcare System Geriatric Research Education Clinical Center, HSR&D Center, Nashville23Department of Medicine, Vanderbilt University, Nashville, Tennessee.
Ronald I ShorrDepartment of Epidemiology, University of Florida, Gainesville25Geriatric Research, Education, and Clinical Center, Malcom Randall Veterans Administration Medical Center, Gainesville, Florida.
Kaycee M SinkSection on Gerontology and Geriatric Medicine, Wake Forest School of Medicine, Department of Internal Medicine, Winston-Salem, North Carolina.
Virginia G WadleyDepartment of Medicine, University of Alabama, Birmingham.
Paul K WheltonDepartment of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana.
Jeffrey WhittleDepartment of Medicine, Medical College of Wisconsin, Milwaukee29Primary Care Division, Clement J. Zablocki Veterans Affairs Medical Center, Milwaukee, Wisconsin.
Nancy F WoolardSection on Gerontology and Geriatric Medicine, Wake Forest School of Medicine, Department of Internal Medicine, Winston-Salem, North Carolina.
Jackson T WrightDivision of Nephrology and Hypertension, Department of Medicine, Case Western Reserve University, Cleveland, Ohio.
Nicholas M PajewskiDivision of Public Health Sciences, Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, North Carolina.
SPRINT Research Group
Wake Forest University · USUniversity of Alabama at Birmingham · USCase Western Reserve University · USEdith Nourse Rogers Memorial Veterans Hospital · USGeriatric Research Education and Clinical Center · USInstitute on Aging · USJohnson University · USMalcom Randall VA Medical Center · USMayo Clinic in Florida · USMedical University of South Carolina · USMilwaukee VA Medical Center · USNational Heart Lung and Blood Institute · USOchsner Health System · USStanford University · USTulane University · USVA San Diego Healthcare System · USVA Tennessee Valley Healthcare System · US

Funding

INSTITUTIONAL CLINICAL AND TRANSLATIONAL SCIENCE AWARDUL1RR024134 · NCRR · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2006 to 2011
$70.4M
University of Pittsburgh Clinical and Translational Science InstituteUL1TR000005 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2012 to 2015
$50.8M
Clinical and Translational Science Collaborative of ClevelandUL1TR000439 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI KONSTAN, MICHAEL W. · 2012 to 2016
$50.0M
Michigan Institute for Clinical and Health Research (MCHR)UL1TR000433 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MASHOUR, GEORGE ALEXANDER · 2012 to 2016
$49.9M
The Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4M
Institutional Clinical and Translational Science AwardUL1TR000003 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2012 to 2015
$38.9M
Using social networks to map and evaluate team science across CTSA hubsUL1TR001427 · NCATS · UNIVERSITY OF FLORIDA · PI MITCHELL, DUANE A. · 2015 to 2024
$37.2M
Spectrum Stanford Center for clinical and Translational Research and EducationUL1TR001085 · NCATS · STANFORD UNIVERSITY · PI CULLEN, MARK RICHARD, GREENBERG, HARRY BERNARD · 2013 to 2017
$37.1M
Wake Forest Claude D. Pepper OAIC - RenewalP30AG021332 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Jamie Nicole Justice · 2002 to 2026
$36.4M
Tufts Clinical and Translational Research InstituteUL1TR001064 · NCATS · TUFTS UNIVERSITY BOSTON · PI SELKER, HARRY P. · 2013 to 2017
$26.4M
University of Iowa Clinical and Translational Science Program (TL1)UL1RR025755 · NCRR · OHIO STATE UNIVERSITY · PI JACKSON, REBECCA D · 2008 to 2011
$26.3M
The Ohio State University Center for clinical and Translational ScienceUL1TR001070 · NCATS · OHIO STATE UNIVERSITY · PI JACKSON, REBECCA D · 2013 to 2017
$22.6M
NCATS NIH HHS 9U54TR000017-06NCATS NIH HHS UL1 TR000002NCATS NIH HHS UL1 TR000003NCATS NIH HHS UL1TR000003NCATS NIH HHS UL1 TR000005NCATS NIH HHS UL1TR000005NCATS NIH HHS UL1 TR000050NCATS NIH HHS UL1TR000050NCATS NIH HHS UL1 TR000064NCATS NIH HHS UL1 TR000073NCATS NIH HHS UL1TR000073NCATS NIH HHS UL1 TR000075NCATS NIH HHS UL1TR000075NCATS NIH HHS UL1 TR000093NCATS NIH HHS UL1TR000093NCATS NIH HHS UL1 TR000105NCATS NIH HHS UL1TR000105-05NCATS NIH HHS UL1 TR000433NCATS NIH HHS UL1TR000433NCATS NIH HHS UL1 TR000439NCATS NIH HHS UL1TR000439NCATS NIH HHS UL1 TR000445NCATS NIH HHS UL1 TR001064NCATS NIH HHS UL1TR001064NCATS NIH HHS UL1 TR001070NCATS NIH HHS UL1 TR001085NCATS NIH HHS UL1 TR001427NCRR NIH HHS UL1 RR024134NCRR NIH HHS UL1RR024134NCRR NIH HHS UL1 RR025752NCRR NIH HHS UL1RR025752NCRR NIH HHS UL1 RR025755NCRR NIH HHS UL1RR025755NCRR NIH HHS UL1 RR025771NCRR NIH HHS UL1RR025771NHLBI NIH HHS 01-HL10741NHLBI NIH HHS A-HL-13-002-001NHLBI NIH HHS HHSN268200900040CNHLBI NIH HHS HHSN268200900046CNHLBI NIH HHS HHSN268200900047CNHLBI NIH HHS HHSN268200900048CNHLBI NIH HHS HHSN268200900049CNHLBI NIH HHS R01 HL107241NHLBI NIH HHS R01 HL107257NHLBI NIH HHS R01 HL130500NIA NIH HHS P30 AG021332NIA NIH HHS P30-AG21332NIGMS NIH HHS P30 GM103337NIGMS NIH HHS P30GM103337PHS HHS HHSN268200900040CPHS HHS HHSN268200900046CPHS HHS HHSN268200900047CPHS HHS HHSN268200900048CPHS HHS HHSN268200900049C
6 · The paper itself

Abstract

importanceThe appropriate treatment target for systolic blood pressure (SBP) in older patients with hypertension remains uncertain.

objectiveTo evaluate the effects of intensive (<120 mm Hg) compared with standard (<140 mm Hg) SBP targets in persons aged 75 years or older with hypertension but without diabetes. DESIGN, SETTING, AND

participantsA multicenter, randomized clinical trial of patients aged 75 years or older who participated in the Systolic Blood Pressure Intervention Trial (SPRINT). Recruitment began on October 20, 2010, and follow-up ended on August 20, 2015.

interventionsParticipants were randomized to an SBP target of less than 120 mm Hg (intensive treatment group, n = 1317) or an SBP target of less than 140 mm Hg (standard treatment group, n = 1319). MAIN OUTCOMES AND MEASURES: The primary cardiovascular disease outcome was a composite of nonfatal myocardial infarction, acute coronary syndrome not resulting in a myocardial infarction, nonfatal stroke, nonfatal acute decompensated heart failure, and death from cardiovascular causes. All-cause mortality was a secondary outcome.

resultsAmong 2636 participants (mean age, 79.9 years; 37.9% women), 2510 (95.2%) provided complete follow-up data. At a median follow-up of 3.14 years, there was a significantly lower rate of the primary composite outcome (102 events in the intensive treatment group vs 148 events in the standard treatment group; hazard ratio [HR], 0.66 [95% CI, 0.51-0.85]) and all-cause mortality (73 deaths vs 107 deaths, respectively; HR, 0.67 [95% CI, 0.49-0.91]). The overall rate of serious adverse events was not different between treatment groups (48.4% in the intensive treatment group vs 48.3% in the standard treatment group; HR, 0.99 [95% CI, 0.89-1.11]). Absolute rates of hypotension were 2.4% in the intensive treatment group vs 1.4% in the standard treatment group (HR, 1.71 [95% CI, 0.97-3.09]), 3.0% vs 2.4%, respectively, for syncope (HR, 1.23 [95% CI, 0.76-2.00]), 4.0% vs 2.7% for electrolyte abnormalities (HR, 1.51 [95% CI, 0.99-2.33]), 5.5% vs 4.0% for acute kidney injury (HR, 1.41 [95% CI, 0.98-2.04]), and 4.9% vs 5.5% for injurious falls (HR, 0.91 [95% CI, 0.65-1.29]). CONCLUSIONS AND RELEVANCE: Among ambulatory adults aged 75 years or older, treating to an SBP target of less than 120 mm Hg compared with an SBP target of less than 140 mm Hg resulted in significantly lower rates of fatal and nonfatal major cardiovascular events and death from any cause.

trial registrationclinicaltrials.gov Identifier: NCT01206062.

Indexed as

Acute Coronary SyndromeAgedAged, 80 and overAntihypertensive AgentsBlood PressureBlood Pressure DeterminationCause of DeathFemaleHeart FailureHumansHypertensionMaleMyocardial InfarctionAntihypertensive Agents

Identifiers

PMID27195814
PMCPMC4988796
OpenAlexW2402203869

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.